Drug Trial Radar · NCT06633718
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Last checked: Nov 19, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
786
Planned (sponsor's estimate)
Start
Oct 31, 2024
Primary completion
May 30, 2027
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with Metronidazole in the treatment of adult complicated intra-abdominal infections (cIAI).
Conditions
- Intra-abdominal Infections
Interventions
Meropenem and PralurbactamDrug
3g,q8h,120min infusion
SalineDrug
100mL,q8h,60min infusion
Ceftazidime-avibactamDrug
2.5g,q8h,120min infusion
MetronidazoleDrug
0.915g,q8h,60min infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Clinical Response of "Cure" at the Test of Cure (TOC) VisitTime frame: Up to approximately 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.